Main Content start here

Report Description

Global intravenous iron drugs market is anticipated to grow at a significant rate in the forecast years, 2024-2028. Rising prevalence of iron deficiency coupled with upsurge in chronic renal disease patients undergoing dialysis are projected to augment the growth of intravenous iron drug market. Anemia is the most common blood disorders which is caused due to the iron deficiency. According to the American Society of Hematology, anemia is one of the most common blood disorders in the United States and has affected over 3 million people in the country. Anemia is highly prevalent in pregnant women and can be harmful to baby. According to the Vitamin and Mineral Nutrition Information System (VMNIS) survey, about 40% of mothers and children in developing nations are anemic. Additionally, rising research and development (R&D) activities in intravenous iron, along with rising government funding for the research is expected to propel the growth of the market.

The market of global intravenous iron drugs is segmented into application, product, end-user, company and region. The end-use segment is further fragmented into hospitals & clinics, ambulatory care, homecare, and others. Hospitals & clinics is expected to dominate the market in the coming years as they are the major centers for providing intravenous iron drugs to people. Also, the rising number of people suffering from anemia, or iron deficiency is contributing for the growth of the segment.

Based on regional analysis, North America is the dominant region in 2022. This is attributed to the rise in the number of anemic patients over the past years. Also, the lack of iron deficiency due to lifestyle changes, unhealthy eating choices and others are expected to impel the growth of the segment.  On the other hand, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period on account of the rising awareness amongst people regarding chronic diseases such as anemia, etc.

Major players operating in the global intravenous iron drugs market include AMAG pharmaceuticals, Inc., Vifor Pharma Group, Daiichi Sankyo Company, Limited, Sanofi SA, Rockwell Medical Inc., Allergan PLC, Pfizer Inc, Nippon Shinyaku Co., Novartis International AG, Takeda Pharmaceutical Company Limited, and Bausch Health Companies Inc.. The companies tend to adopt various organic and inorganic strategies to sustain in the market of intravenous iron drugs.


Download Free Sample Report

Objective of the Study:

  • To analyze and estimate the market size of global intravenous iron drugs market from 2018 to 2021.
  • To estimate and forecast the market size of global intravenous iron drugs market from 2022 to 2028 and growth rate until 2028.
  • To classify and forecast global intravenous iron drugs market, the market is categorized on the basis of application, product, end-user, company and region.
  • To identify dominant region or segment in the global intravenous iron drugs market.
  • To identify drivers and challenges for global intravenous iron drugs market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global intravenous iron drugs market.
  • To conduct pricing analysis for global intravenous iron drugs market.
  • To identify and analyze the profile of leading players operating in global intravenous iron drugs market.
  • To identify key sustainable strategies adopted by market players in global intravenous iron drugs market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global intravenous iron drugs market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Intravenous iron drugs key players, suppliers, distributors, and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to intravenous iron drugs
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Attribute

Details

Base Year

2022

Historical Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, Volume in Units and CAGR for 2018-2022 and 2023E-2028F

Report coverage

Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends

Segments covered

        Application

         Product

         End User 

         Region

Regional scope

North America; Europe; Asia Pacific; South America; Middle East & Africa

Country scope

United States, Mexico, Canada, China, India, Japan, South Korea, Australia; Germany, France, United Kingdom, Spain, Italy; South Africa, UAE, Saudi Arabia; Brazil, Argentina, Colombia;

Key companies profiled

AMAG pharmaceuticals, Inc., Vifor Pharma Group, Daiichi Sankyo Company, Limited, Sanofi SA, Rockwell Medical Inc., Allergan PLC, Pfizer Inc, Nippon Shinyaku Co., Novartis International AG, Takeda Pharmaceutical Company Limited, and Bausch Health Companies Inc.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global intravenous iron drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Intravenous Iron Drugs Market, By Application:
    • Intestinal malabsorption syndromes
    • Inflammatory diseases
    • Gastrectomy/bariatric surgery
    • Anemia
    • Osier-Weber-Rendu disease
    • Angiodysplasia
    • Pregnancy
    • Others
  • Global Intravenous Iron Drugs Market, By Product:
    • Iron dextran
    • Ferric gluconate
    • Iron sucrose
    • Ferric carboxymaltos
    • Iron isomaltoside 100
    • Ferumoxytol
  • Global Intravenous Iron Drugs Market, By End-User:
    • Hospitals & Clinics
    • Ambulatory Care
    • Homecare
    • Others
  • Global Intravenous iron drugs Market, By Region:
    • Asia-Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • North America
      • United States
      • Mexico
      • Canada
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE 

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Intravenous iron drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global intravenous iron drugs market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]  

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Intravenous Iron Drugs Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value & Volume

5.2.  Market Share & Forecast

5.2.1.     By Application (Intestinal malabsorption syndromes, Inflammatory diseases, Gastrectomy/bariatric surgery, Anemia, Osier-Weber-Rendu disease, Angiodysplasia, Pregnancy, Others)

5.2.2.     By Product (Iron dextran, Ferric gluconate, Iron sucrose, Ferric carboxymaltos, Iron isomaltoside 1000, Ferumoxytol)

5.2.3.     By End-User (Hospitals & Clinics, Ambugalotry Care, Homecare, Others)

5.2.4.     By Company (2022)

5.2.5.     By Region

5.3.  Market Map

6.    Clinical Trial Analysis

6.1.  Ongoing Clinical Trials

6.2.  Completed Clinical Trials

6.3.  Terminated Clinical Trials

6.4.  Breakdown of Pipeline, By Development Phase

6.5.  Breakdown of Pipeline, By Status

6.6.  Breakdown of Pipeline, By Study Type

6.7.  Breakdown of Pipeline, By Country

6.8.  Clinical Trials Heat Map

7.    Asia-Pacific Intravenous Iron Drugs Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value & Volume

7.2.  Market Share & Forecast

7.2.1.     By Application

7.2.2.     By Product

7.2.3.     By End-User

7.2.4.     By Country

7.3.  Asia-Pacific: Country Analysis

7.3.1.     China Intravenous Iron Drugs Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Application

7.3.1.2.2.             By Product

7.3.1.2.3.             By End-User

7.3.2.     India Intravenous Iron Drugs Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Application

7.3.2.2.2.             By Product

7.3.2.2.3.             By End-User

7.3.3.     Japan Intravenous Iron Drugs Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Application

7.3.3.2.2.             By Product

7.3.3.2.3.             By End-User

7.3.4.     South Korea Intravenous Iron Drugs Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Application

7.3.4.2.2.             By Product

7.3.4.2.3.             By End-User

7.3.5.     Australia Intravenous Iron Drugs Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Application

7.3.5.2.2.             By Product

7.3.5.2.3.             By End-User

8.    Europe Intravenous Iron Drugs Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value & Volume

8.2.  Market Share & Forecast

8.2.1.     By Application

8.2.2.     By Product

8.2.3.     By End-User

8.2.4.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Intravenous Iron Drugs Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Application

8.3.1.2.2.             By Product

8.3.1.2.3.             By End-User

8.3.2.     Germany Intravenous Iron Drugs Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Application

8.3.2.2.2.             By Product

8.3.2.2.3.             By End-User

8.3.3.     United Kingdom Intravenous Iron Drugs Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Application

8.3.3.2.2.             By Product

8.3.3.2.3.             By End-User

8.3.4.     Italy Intravenous Iron Drugs Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Application

8.3.4.2.2.             By Product

8.3.4.2.3.             By End-User

9.    North America Intravenous Iron Drugs Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value & Volume

9.2.  Market Share & Forecast

9.2.1.     By Application

9.2.2.     By Product

9.2.3.     By End-User

9.2.4.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Intravenous Iron Drugs Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Application

9.3.1.2.2.             By Product

9.3.1.2.3.             By End-User

9.3.2.     Mexico Intravenous Iron Drugs Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Application

9.3.2.2.2.             By Product

9.3.2.2.3.             By End-User

9.3.3.     Canada Intravenous Iron Drugs Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Application

9.3.3.2.2.             By Product

9.3.3.2.3.             By End-User

10.  South America Intravenous Iron Drugs Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value & Volume

10.2.              Market Share & Forecast

10.2.1.  By Application

10.2.2.  By Product

10.2.3.  By End-User

10.2.4.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Intravenous Iron Drugs Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Application

10.3.1.2.2.           By Product

10.3.1.2.3.           By End-User

10.3.2.  Argentina Intravenous Iron Drugs Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Application

10.3.2.2.2.           By Product

10.3.2.2.3.           By End-User

10.3.3.  Colombia Intravenous Iron Drugs Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Application

10.3.3.2.2.           By Product

10.3.3.2.3.           By End-User

11.  Middle East and Africa Intravenous Iron Drugs Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value & Volume

11.2.              Market Share & Forecast

11.2.1.  By Application

11.2.2.  By Product

11.2.3.  By End-User

11.2.4.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Intravenous Iron Drugs Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Application

11.3.1.2.2.           By Product

11.3.1.2.3.           By End-User

11.3.2.  Saudi Arabia Intravenous Iron Drugs Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Application

11.3.2.2.2.           By Product

11.3.2.2.3.           By End-User

11.3.3.  UAE Intravenous Iron Drugs Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Application

11.3.3.2.2.           By Product

11.3.3.2.3.           By End-User

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1.              Competition Outlook

14.2.              Players Profiled (Leading Companies)

14.2.1.  AMAG pharmaceuticals, Inc.

14.2.2.  Vifor Pharma Management Ltd.

14.2.3.  Daiichi Sankyo Company, Limited

14.2.4.  Rockwell Medical Inc.

14.2.5.  Allergan PLC

14.2.6.  Pfizer Inc

14.2.7.  Nippon Shinyaku Co.

14.2.8.  Novartis International AG

14.2.9.  Takeda Pharmaceutical Company Limited

14.2.10.                Bausch Health Companies Inc.

15. Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

Increasing cases of renal disease and growing patient pool are expected to drive global intravenous iron drugs during the forecast period.

down-arrow

The market of global intravenous iron drugs is segmented on the basis of application, product, end-user, company and region.

down-arrow

Based on end-use, clinics segment is expected to hold the largest share in global intravenous iron drugs market during forecast period.

down-arrow

Major players operating in the global intravenous iron drugs market include AMAG pharmaceuticals, Inc., Vifor Pharma Group, Daiichi Sankyo Company, Limited, Sanofi SA, Rockwell Medical Inc., Allergan PLC, Pfizer Inc, Nippon Shinyaku Co., Novartis International AG, Takeda Pharmaceutical Company Limited, and Bausch Health Companies Inc.

profile

Sakshi Bajaal

Business Consultant
Press Release

Intravenous Iron Drugs Market to Grow at a Brisk Rate During Forecast Period

Sep, 2020

Increasing cases of renal disease and growing requirement of dialysis to drive global intravenous iron drugs through 2025